Xiangyu Zhong | Medicine | Best Researcher Award

Posted on by ScienceFather

Prof. Xiangyu Zhong | Medicine | Best Researcher Award

Prof. Xiangyu Zhong, The 2nd Affiliated Hospital of Harbin Medical University, China

Professor Xiangyu Zhong is a distinguished academic and chief physician at the Department of General Surgery, The 2nd Affiliated Hospital of Harbin Medical University, China. With a robust background in medicine and extensive clinical experience, his research primarily focuses on cholangiocarcinoma, Metabolic Associated Fatty Liver Disease (MAFLD), and hepatic ischemia-reperfusion injury.

Professional Profiles:

Scopus

Professional Experience:

Prof. Xiangyu Zhong is a distinguished academician with a robust educational background in medicine. He serves as a Professor and Chief Physician in the Department of General Surgery at the Second Affiliated Hospital of Harbin Medical University. With extensive clinical expertise, he has significantly contributed to medical research, particularly in the fields of cholangiocarcinoma, Metabolic Associated Fatty Liver Disease (MAFLD), and hepatic ischemia-reperfusion injury. His academic journey is complemented by 57 publications in SCI/Scopus indexed journals, with a citation index of 1172, solidifying his position as a leading researcher in his field.

Research Interests:

Prof. Zhong’s research is focused on cholangiocarcinoma, MAFLD, and hepatic ischemia-reperfusion injury. His work has substantially enhanced the understanding of these diseases, offering valuable insights into their pathogenesis and potential therapeutic approaches. With three ongoing research projects, his contributions continue to shape the future of clinical treatments and patient care in liver diseases. Although there are no consultancy or industry projects, Prof. Zhong’s research alone has garnered significant recognition, evidenced by his numerous publications and citation index. His contributions have directly impacted advancements in surgical techniques and liver disease management.

Contributions and Impact:

Prof. Zhong’s impactful research has led to significant advancements in understanding complex liver diseases such as cholangiocarcinoma, MAFLD, and hepatic ischemia-reperfusion injury. His work, which has been cited over 1,100 times, is widely recognized for providing new insights and therapeutic approaches that directly benefit patient care. The depth of his research has influenced both the scientific community and clinical practices, furthering knowledge in areas critical for the treatment of liver-related ailments. With a high citation index and numerous peer-reviewed publications, his work continues to drive innovation in liver surgery and related fields.

Publications:

Circ_0007534 Promotes Cholangiocarcinoma Stemness and Resistance to Anoikis through DDX3X-Mediated Positive Feedback Regulation of Parental Gene DDX42
Liu, S., Guan, C., Sha, X., Zhong, X., Jiang, X.
Cellular Signalling, 2024, 118, 111141

Open access

0 citations

Utilization of 3D Printing Technology in Hepatopancreatobiliary Surgery
Shi, W., Wang, J., Gao, J., Cui, Y., Zhong, X.
Journal of Zhejiang University: Science B, 2024, 25(2), pp. 123–134

Open access

1 citation

Forkhead Box O1 in Metabolic Dysfunction-Associated Fatty Liver Disease: Molecular Mechanisms and Drug Research
Sha, X., Zou, X., Liu, S., Zhong, X., Jiang, X.
Frontiers in Nutrition, 2024, 11, 1426780

Open access

1 citation

Research Progress and Applications of Epigenetic Biomarkers in Cancer
Gao, J., Shi, W., Wang, J., Zhong, X., Cui, Y.
Frontiers in Pharmacology, 2024, 15, 1308309

Open access

1 citation

Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Gao, J., Wang, J., Guan, C., Xu, X., Zhong, X.
Journal of Cancer, 2024, 15(8), pp. 2214–2228

Open access

0 citations

Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma
Yang, C., Dong, Q., Bao, H., Xu, Y., Zhong, X.
Frontiers in Bioscience – Landmark, 2024, 29(1), 45

Open access

0 citations

Cullin-Associated and Neddylation-Dissociated Protein 1 (CAND1) Alleviates NAFLD by Reducing Ubiquitinated Degradation of ACAA2
Huang, X., Liu, X., Li, X., Yang, B., Pan, Z.
Nature Communications, 2023, 14(1), 4620

Open access

5 citations

Retraction: The Prognostic Potential and Carcinogenesis of Long Non-Coding RNA TUG1 in Human Cholangiocarcinoma
Xu, Y., Leng, K., Li, Z., Jiang, X., Cui, Y.
Oncotarget, 2023, 14, pp. 779

Retraction

0 citations

Application of Normothermic Regional Perfusion in Controlled Donation After Cardiac Death Liver Transplant Donors
Zou, X., Huang, Z., Shi, W., Cui, Y., Zhong, X.
China Journal of General Surgery, 2023, 32(7), pp. 1087–1096

Open access

1 citation

Exosomal miRNAs in the Microenvironment of Pancreatic Cancer
Zou, X., Huang, Z., Guan, C., Xu, Y., Zhong, X.
Clinica Chimica Acta, 2023, 544, 117360

Open access

1 citation

Conclusion:

Prof. Xiangyu Zhong is undoubtedly a strong contender for the Best Researcher Award due to his extensive research contributions, leadership in collaborative efforts, and impact on medical and therapeutic advancements. While there are areas where improvement could further elevate his profile, such as increasing citations and expanding clinical research involvement, his overall academic impact, innovation, and leadership make him a deserving candidate. His work not only contributes to fundamental science but also holds significant promise for improving patient care and treatment outcomes, which is at the core of the Best Researcher Award’s mission.